Drug Trial Radar · NCT03020992
A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU
Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
89
Actual
Start
Dec 21, 2016
Primary completion
Dec 4, 2019
Study completion Jan 23, 2020
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Jan 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to demonstrate the effect of Certolizumab Pegol (CZP) treatment on the reduction of Anterior Uveitis (AU) flares in subjects with active axial Spondyloarthritis (axSpA) and a documented history of AU.
Conditions
- Axial Spondyloarthritis (axSpA)
- Anterior Uveitis (AU)
Interventions
Certolizumab PegolDrug
* pharmaceutical form: solution for infusion in prefilled syringe * concentration: 200 mg/mL * route of administration: subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Distinct Episodes of Anterior Uveitis (AU) Flares During the Treatment PeriodTime frame: During the pre-study period and during the Treatment Period up to 96 weeks
Locations
23 sites in 5 countries. Site status is shown where the registry gives one.
As0007 101
Brno, Czechia
As0007 103
Brno, Czechia
As0007 107
Brno, Czechia
As0007 108
Ostrava, Czechia
As0007 109
Pardubice, Czechia
As0007 102
Prague, Czechia
As0007 105
Prague, Czechia
As0007 301
Freiburg im Breisgau, Germany
As0007 302
München, Germany
As0007 303
Münster, Germany
As0007 401
Amsterdam, Netherlands
As0007 506
Bialystok, Poland
As0007 510
Lublin, Poland
As0007 509
Poznan, Poland
As0007 511
Poznan, Poland
As0007 502
Torun, Poland
As0007 501
Warsaw, Poland
As0007 505
Warsaw, Poland
As0007 504
Wroclaw, Poland
As0007 507
Wroclaw, Poland
As0007 508
Wroclaw, Poland
As0007 604
Barcelona, Spain
As0007 601
Córdoba, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.